Manipulation of radiobiological hypoxia in a human melanoma xenograft to exploit the bioreductive cytotoxicity of RSU-1069.
Cole
S
S
MRC Radiobiology Unit, Didcot, Oxon, U.K.
Stratford
I J
IJ
Adams
G E
GE
D000818:Animals; D015687:Cell Hypoxia / Q000187:drug effects / Q000502:physiology*; D003131:Combined Modality Therapy; D003250:Constriction; D005260:Female; D006830:Hydralazine / Q000627:therapeutic use; D008545:Melanoma / Q000098:blood supply / Q000188:drug therapy / Q000532:radiotherapy*; D051379:Mice; D008819:Mice, Nude; D008920:Misonidazole / Q000031:analogs & derivatives* / Q000627:therapeutic use; D009368:Neoplasm Transplantation; D011838:Radiation-Sensitizing Agents / Q000627:therapeutic use*; D014183:Transplantation, Heterologous
D011838:Radiation-Sensitizing Agents; D006830:Hydralazine; C041712:1-(2-nitro-1-imidazolyl)-3-aziridino-2-propanol; D008920:Misonidazole